The European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) convened from May 13 to 15, 2025, in Amsterdam to deliberate on critical veterinary medicinal approvals and regulatory enhancements. The in-person meeting focused on evaluating maximum residue limits, approving new marketing authorizations, and appointing key figures to various working parties, underscoring the agency’s commitment to advancing animal health and safety standards across the European Union.
Key Approvals and Recommendations
During the session, the CVMP adopted opinions on multiple substances, including lidocaine for porcine use and innovative vaccines targeting diseases in chickens and dogs. Notably, the committee approved Fluralaner Intervet, a systemic insecticide for dogs, highlighting its efficacy in controlling fleas and ticks. Additionally, Nobilis Multriva IBm+ND+Gm+REOm+EDS vaccine for chickens received endorsement, aiming to reduce respiratory issues and mortality rates associated with various avian diseases. These approvals reflect the CVMP’s rigorous assessment processes to ensure the safety and effectiveness of veterinary medicines.
Regulatory Enhancements and Working Party Appointments
The meeting also saw the re-election of Johan Schefferlie as the CVMP chair and the election of Mark Montforts as the new chair for the Environmental Risk Assessment Working Party (ERAWP). Furthermore, Anja Pfalzgraff was appointed Vice-chair of the Novel Therapies & Technologies Working Party (NTWP), signaling a strategic focus on advancing veterinary medical technologies. The committee adopted a reflection paper on Regulation (EU) 2019/6, aiming to streamline variations in marketing authorizations and enhance regulatory compliance across member states.
- Approval of Fluralaner Intervet marks a significant advancement in flea and tick control for dogs.
- New vaccines for chickens demonstrate the CVMP’s proactive approach in managing avian diseases.
- Leadership appointments indicate a strengthened focus on environmental risk and novel therapies.
- Regulatory reflections aim to harmonize veterinary medicinal standards across the EU.
EMA’s CVMP continues to play a pivotal role in ensuring the availability of safe and effective veterinary medicines. By approving new treatments and refining regulatory measures, the committee not only safeguards animal health but also supports the agricultural and companion animal sectors. These efforts contribute to the broader goals of public health and food safety, reinforcing the EU’s leadership in veterinary pharmaceutical regulation. Stakeholders and practitioners can anticipate ongoing enhancements in veterinary care standards, driven by the CVMP’s comprehensive evaluations and strategic initiatives.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
